Alyaev Yu G, Rudenko V I, Perekalina A N, Kraev I G, Inoyatov Zh Sh
Department of Urology, Sechenov First Moscow State Medical University, Moscow.
Urologiia. 2016 Apr(2 Suppl 2):103-110.
Numerous metabolic abnormalities intrinsic to urolithiasis require drug therapy. At the same time, despite the constant expansion of synthetic drugs, plant-derived medications play a large role in the treatment and prevention of the disease.
To evaluate the effect of a plant-derived preparation Rowatinex in patients with urolithiasis after extracorporeal shock wave lithotripsy (ESWL) and analyze the changes in blood and urine parameters in patients receiving the preparation.
Depending on the type of post-ESWL treatment, patients were divided into two groups. After ESWL, patients of group A (n=107) and group B (n=50) were administered Rowatinex and antispasmodic drugs, respectively.
Clearance of stone fragments after ESWL within 1-5 days was achieved in 76 (71.1%) patients of group A and in 20 (40.4%) of group B. Analysis of the effect of the therapy on blood count, biochemistry tests and 24h excretion (magnesium, uric acid, calcium, etc.) did not reveal significant differences between group A group B and reference values. Increased diuresis caused by antispasmodic effects of Rowatinex resulted in the complete clearance of stone fragments. Urinalysis in patients of the two groups showed decreased leukocyturia. Furthermore, stabilization of urine pH within the 6.2-6.8 was noted in group A, which is important and necessary in metaphylaxis of recurrent stone formation.
Administration of Rowatinex increases the percentage of stone fragment clearance after ESWL and reduces pain intensity. Rowatinex reduces leukocyturia, increases 24h diuresis and stabilizes the pH of urine. Increasing and stabilizing urine pH in patients with calcium oxalate and urate stones reduces the risk of recurrence after ESWL. No complications associated with Rowatinex were reported, allowing long-term administration of the preparation in the complex lithokinetic therapy and for metaphylaxis of recurrent stone formation.
尿石症存在许多内在的代谢异常，需要药物治疗。与此同时，尽管合成药物不断增加，但植物源药物在该疾病的治疗和预防中发挥着重要作用。
评估植物源制剂Rowatinex对体外冲击波碎石术（ESWL）后尿石症患者的疗效，并分析接受该制剂治疗患者的血液和尿液参数变化。
根据ESWL后的治疗类型，将患者分为两组。ESWL后，A组（n = 107）和B组（n = 50）患者分别给予Rowatinex和抗痉挛药物。
A组76例（71.1%）患者和B组20例（40.4%）患者在ESWL后1 - 5天内实现了结石碎片清除。对治疗对血细胞计数、生化检查和24小时排泄（镁、尿酸、钙等）的影响分析显示，A组和B组与参考值之间无显著差异。Rowatinex的抗痉挛作用导致利尿增加，从而使结石碎片完全清除。两组患者的尿液分析显示白细胞尿减少。此外，A组患者尿液pH稳定在6.2 - 6.8之间，这在预防复发性结石形成中很重要且必要。
服用Rowatinex可提高ESWL后结石碎片清除率并减轻疼痛强度。Rowatinex可减少白细胞尿，增加24小时尿量并稳定尿液pH。对于草酸钙和尿酸盐结石患者，提高并稳定尿液pH可降低ESWL后复发风险。未报告与Rowatinex相关的并发症，因此该制剂可在复杂的排石治疗中长期使用，并用于预防复发性结石形成。
